Just out todayDigital health tech: Ninety-nine nurses, seventy wearable features, and no control groupDigital health tech: Fifty-six trials, 6,154 patients, and headsets beat the threshold patients would noticeSynthetic biology & cell therapy: Roughly one in four patients on these therapies gets a severe infection

Robotics/Norway, Finland

A trial that reports how many patients said yes, which is the question it asked

A double-blind feasibility trial randomised 40 of 160 prostatectomy patients to perioperative propranolol or placebo.

What the paper found

A trial at Oslo University Hospital randomised 40 patients undergoing robotic-assisted radical prostatectomy to perioperative propranolol or placebo, double-blind, to establish feasibility and safety. Of 160 patients operated over 36 weeks, 111 were prescreened, 49 fully screened and 40 randomised. No severe adverse events were attributed to propranolol and no surgery was delayed.

Grade 13 reading level6 min read

What happened

A team at the Norwegian Radium Hospital, part of Oslo University Hospital, with the University of Oslo, published in BJUI Compass a randomised, double-blind, placebo-controlled pilot trial of perioperative propranolol in men undergoing robotic-assisted radical prostatectomy.

Participants were randomised 1:1 to propranolol or placebo for approximately three weeks: about one week before surgery and two weeks after.

The trial’s stated aim was feasibility and safety, not efficacy.

Over 36 weeks in 2023, 160 patients underwent the operation. 111 were prescreened, 49 fully screened, and 40 randomised. That is 36% inclusion among prescreened patients and 82% among fully screened.

Pre-surgery adherence was 98% in both arms. Post-surgery adherence was lower in the propranolol arm.

The test

The underlying hypothesis comes from laboratory and observational work suggesting that the surgical stress response, which involves catecholamine release, may help circulating tumour cells establish themselves. Blocking beta-adrenergic signalling around the time of surgery is a cheap, well-understood intervention if it works.

Testing that properly needs a large trial with long follow-up. Before committing to one, the sensible question is whether patients facing a cancer operation will enrol in a placebo-controlled drug trial and take the tablets.

This trial answers that, and the outcome measures reflect it: recruitment rates, adherence and safety, graded by CTCAE version 5.0.

The trial is double-blind and placebo-controlled, which is the right design even for a feasibility question, because adherence and side-effect reporting depend on blinding holding.

The numbers

Item Value
Design randomised, double-blind, placebo-controlled pilot
Intervention period about 3 weeks (1 week pre, 2 weeks post surgery)
Operations performed in window 160 over 36 weeks in 2023
Prescreened 111
Fully screened 49
Randomised 40
Inclusion rate, prescreened 36%
Inclusion rate, fully screened 82%
Pre-surgery adherence 98% both arms
Post-surgery adherence lower in propranolol arm
CTCAE grade 3+ events attributed to propranolol none
Surgeries delayed none

The result

Read the funnel: 160 operations, 111 prescreened, 49 fully screened, 40 randomised. One quarter of the operative stream entered the trial.

The two inclusion rates tell different stories. 36% of prescreened patients were randomised, which is the number a trial planner needs for site selection. 82% of fully screened patients were randomised, which says that once a patient reached full screening they almost always agreed. The attrition is therefore in the gap between prescreening and full screening, not in patient refusal.

The safety result is clean: no severe adverse events attributed to the drug, and no surgery delayed. For a trial adding a drug to a cancer operation, not delaying any operation is the bar that matters.

The adherence asymmetry is the finding that will shape the definitive trial. Identical 98% adherence before surgery and lower adherence on propranolol afterwards is the signature of a drug whose effects patients notice. Propranolol slows the heart and can cause fatigue, so differential post-operative adherence by arm is both plausible and a threat to blinding.

How this compares to what came before

Among this batch’s robotic surgery papers, this is the only one not asking about the robot. The robotic prostatectomy is the setting; the intervention is a sixty-year-old beta blocker.

That makes its comparator set the other feasibility and pilot studies here. A digital inclusion pilot randomised 40 digitally excluded kidney patients to establish that the population could be recruited at all. A robot-assisted shoulder rehabilitation pilot had 45 completers and reported a split between objective and subjective outcomes. A headset versus console training study called itself a feasibility study and found no difference between modalities.

Of those four, this trial is the clearest about what a feasibility study is for. It names recruitment and adherence as the outcomes, reports the funnel, and does not report an efficacy signal it was not powered to detect. The shoulder rehabilitation pilot, by contrast, reported significant patient-reported improvements from 45 completers, which is the temptation this trial resisted.

What it means

For trial design in surgical oncology, these numbers are directly reusable. A 36% inclusion rate among prescreened patients and 82% among fully screened tells a planner how many sites and how long a definitive trial needs.

For the propranolol hypothesis specifically, the trial clears the operational hurdle and flags the methodological one. A definitive trial will need to manage differential post-operative adherence, which might mean active-comparator design, dose titration or adherence monitoring built into the protocol.

For readers, the useful discipline is to notice when a paper reports what it set out to measure and stops. This one does.

Business ideas from this paper

Trial feasibility assessment as a service for surgical units: screening funnel analysis, adherence prediction and site capacity modelling, which is what sponsors currently guess at.

Adherence monitoring for short perioperative drug courses, where the window is weeks and conventional adherence tooling is built for chronic medication.

Repurposing pipelines for generic drugs in surgical oncology, where the intervention is cheap and the evidence gap is a trial rather than a molecule.

What could be wrong with it

This is a feasibility trial and establishes nothing about cancer recurrence, which is the hypothesis motivating it.

Forty patients is small even for a feasibility question, and the adherence and safety findings rest on 20 patients per arm.

Lower post-operative adherence in the propranolol arm suggests patients could tell which arm they were in, which weakens the double blind.

Every affiliation resolves to Oslo University Hospital or the University of Oslo, so there is no independent site and the recruitment figures reflect one institution’s patient stream.

The record abstract does not explain the attrition between 111 prescreened and 49 fully screened, which is where most of the funnel loss occurred.

Data are available from the corresponding author on request rather than deposited.

How sure can you be?

Confident in the recruitment funnel, because the numbers are reported at each stage: 160, 111, 49, 40.

Confident that no severe adverse events were attributed to propranolol and that no surgeries were delayed.

Confident that pre-surgery adherence was 98% in both arms.

Less confident that the blind held after surgery, given the adherence asymmetry.

Less confident that these recruitment rates transfer to other centres, since this is one hospital’s stream.

Not confident about anything concerning efficacy, which the trial does not test.

Our rubric places this at the floor of the range for this batch: peer-reviewed, one institution, a randomised double-blind placebo-controlled trial reporting feasibility rather than efficacy, with data available on request.

Do this today

If you are reading a pilot trial, check whether it reports an efficacy signal it was not powered to find. This one does not, which makes its feasibility numbers more trustworthy.

If you are planning a perioperative drug trial, use the funnel: 36% of prescreened and 82% of fully screened is a usable planning assumption.

If adherence differs by arm in a blinded trial, treat the blind as compromised and design the next trial accordingly.

Source: Perioperative propranolol during robotic-assisted radical prostatectomy: A randomised, double-blind, placebo-controlled, pilot trial (PeP-RALP), BJUI Compass, 2026-08-26. PMID 42662047 · doi.org ().

Just Out Tech explains new research in plain language. This article was drafted with AI assistance and checked by a human against the original source.

What to remember
  • Randomised, double-blind, placebo-controlled pilot trial; participants received propranolol or placebo for about three weeks, one week before and two weeks after surgery.
  • Over 36 weeks in 2023, 160 patients underwent the operation: 111 prescreened, 49 fully screened, 40 randomised.
  • Inclusion rates were 36% among prescreened and 82% among fully screened patients.
  • Pre-surgery adherence was 98% in both arms; post-surgery adherence was lower in the propranolol arm. No CTCAE grade 3 or above adverse events were attributed to propranolol and no surgeries were delayed.
Where this really is

Randomised double-blind placebo-controlled pilot trial reporting recruitment, adherence and safety rather than efficacy; single institution.

Questions people ask

What is the hypothesis being set up?

That blunting the perioperative stress response with a beta blocker may reduce the chance of tumour cells seeding during cancer surgery. The evidence for it is laboratory and observational.

Why run a feasibility trial first?

Because a definitive trial is expensive, and if patients will not enrol or will not take the drug after surgery, the definitive trial cannot be run. These numbers decide that.

What does the adherence asymmetry mean?

Pre-surgery adherence was 98% in both arms, and post-surgery adherence was lower on propranolol. Differential adherence by arm usually means patients can tell which arm they are in, which erodes blinding.

Does this tell us anything about cancer recurrence?

No. It is not powered for it and does not report it.

About the author

Mark Alex

Mark Alex is the founder and Managing Director of Real Biz Digital, a technology company operating out of Nairobi since 2018. He works in agentic AI and the Model Context Protocol, AI governance, enterprise software architecture and cybersecurity. He holds an MSc in Mechatronical Engineering from Obuda University in Budapest and a BSc in IT, Forensic Technology and Cybercrime, from USIU-Africa in Nairobi, and has published IEEE conference research on an AI-powered digital twin for greenhouse systems. He is the author of seven books. Between 2020 and 2024 he mentored more than 200 university students and interns in Nairobi. He writes every Just Out Tech article from the original research paper.